ArticleMaterials today. Bio2025
A based
Article in Materials today. Bio, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Spiky mesoporous silica-based nanovaccines enhance mucosal immunity with improved intestinal retention and antigen accessibility.Materials today. Bio · 2026Article
- Benefits and mechanisms of polysaccharides derived from traditional Chinese medicine for ulcerative colitis treatment (Review).Experimental and therapeutic medicine · 2026Review
- Colon-targeted oral delivery of melatonin for regulating macrophage activity and intestinal barrier in ulcerative colitis.Theranostics · 2026Article
- Nanomedicines Reshape the Tumor Microenvironment: Multidimensional Strategies from Modulating "Barriers" to Metabolic Intervention.International journal of nanomedicine · 2026Review
- Polyethyleneimine-modifiedMaterials today. Bio · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Oral vaccines received great interest in preventing of global pandemics due to the ability to facilitate both systemic and mucosal immune responses. However, the enzymatic degradation, low permeability of mucus barrier, and lack of effective and safe mucosal adjuvants continue to remain significant challenge for oral vaccine. Herein, we developed a novel delivery system based on nanoparticles functionalized by plant polysaccharides to address the above challenges. Firstly, the
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.